To investigate if azathioprine could reduce adenoma formation in Apc Min/+ , a mouse model of sporadic intestinal tumorigenesis.
ABSTRACT Aim
To investigate if azathioprine could reduce adenoma formation in Apc Min/+ , a mouse model of sporadic intestinal tumorigenesis.
Methods
Azathioprine was administered via drinking water (estimated 6-20 mg/kg body weight per day) to
Apc
Min/+ and wildtype mice. Control animals received vehicle only (DMSO) dissolved in drinking water.
At 15 weeks of age all mice were sacrificed and intestines of Apc Min/+ were harvested for evaluation of polyp number. Azathioprine induced toxicity was investigated by immunohistochemical analysis on spleens.
Results
All azathioprine treated mice showed signs of drug-associated toxicity such as weight loss and development of splenic T-cell lymphomas. Although this suggests that the thiopurine concentration was clearly in the therapeutic range, it did not reduce tumor formation (48±3.1 vs 59±5.7 adenomas, P = 0.148).
Conclusion
We conclude that in the absence of inflammation, azathioprine does not affect intestinal tumorigenesis. 
INTRODUCTION
The thiopurines azathioprine and 6-mercaptopurine are widely used to induce and maintain remission of inflammatory bowel disease (IBD) [1] [2] [3] [4] . In addition to their immunosuppressive effects, exposure to thiopurines is associated with a substantially reduced risk of developing colorectal cancer in patients with IBD 2, 5 .
The presumed mechanism of action of thiopurines is through selective inhibition of the GTPase RAC1 6, 7 . 
MATERIALS AND METHODS

Mouse experiments
The protocol of this study was approved by the animal ethics committee of the University of Amsterdam (permit number ALC102806). Apc Min/+11 and littermate wild type C57B/6J mice of five weeks old (12 males and 12 females of each genotype) were ordered at the Jacksons Laboratory.
Upon arrival animals were given drinking water in which azathioprine (Sigma Aldrich A4638) was dissolved at 0.04 mg/ml as previously described by others 12 .
The estimated dose was 6-20 mg/kg body weight per day, given that a mouse weighs approximately 20-30 g and drinks approximately
4-8 mL of water per day 12 . Control animals received vehicle only (DMSO) dissolved in drinking water.
We expected mice to develop a mean of 60 polyps (with 10% standard deviation) and reasoned that azathioprine could only be clinically applicable if the polyp number would be reduced by at least 25%.
At a p of 0.05 (alpha 0,025) and power of 0.8, the sample size was calculated for 6 animals by group.
Histological analysis
After paraffin embedding, 4 µm sections were made and used for routine hematoxylin eosin staining. Immunohistochemistry was performed as described previously 13{Heijmans, 2013 11 /id} using the following antibodies: anti-Cd3 (Dako, rabbit polyclonal, A0452), B220. Anti-Cd45R (Biolegend/ITK, rat monoclonal, 103202), anti-Ki67 (Monosan, Rabbit monoclonal, MONX10284), anti-β-catenin (transduction laboratories, mouse monoclonal, 610154). Histological evaluation of spleens was performed by an expert pathologist (MJ).
Statistics
All data are presented as mean ± standard error of the mean. For animal experiments, the MannWhitney test was used. For the analysis of adenoma size distribution, a 2-way ANOVA was used.
RESULTS
Treatment with azathioprine results in severe toxicity in mice
Two weeks after the start of azathioprine administration (dissolved in the drinking water at 0.04 mg/ ml), Apc Min/+ and wild type female mice started to lose weight and became moribund whereas female control mice treated with solvent only continued to gain weight (Figure 1a, b) . According to local animal research guidelines we euthanized mice losing more than 15% of initial weight, resulting in termination of the entire group of 12 female mice receiving azathioprine by the end of the fourth week of treatment. In contrast, male mice did not show any symptoms of drug-associated toxicity at this time point. Post mortem investigation showed signs of profound anemia with discoloration of extremities and internal organs of all azathioprine treated female mice. Upon examination of the intestines, we did not identify polyps in these 9-week-old animals.
In order to reduce potential drug toxicity in the remaining male animals, we lowered the azathioprine dose to 0.02 mg/ml at four weeks after the start of treatment. Although the body weight of male mice remained stable at first, we eventually observed weight loss in male animals.
To prevent further deterioration of the mice, we terminated the experiment at fifteen weeks of age ( Figure 1c ).
Azathioprine treatment results in the development of splenic T-cell lymphomas
We observed enlargement of the spleen in all azathioprine treated mice (both controls and Apc Min/+ mice), but in none of the control animals ( Figure 2a ). The development of splenic lymphomas is a known adverse effect of azathioprine treatment in both humans and mice 14 . We therefore performed further histological evaluation of samples of azathioprine treated control and Apc Min/+ mice. All spleens of azathioprine treated animals showed an expanded red pulp with a pleomorphic population of lymphocytic blasts that displayed prominent variation in nuclear size, contour and atypical mitoses (Figure 2b ). This is diagnostic of a diffuse lymphoproliferative disease. We
performed immunohistochemical staining to further analyze the composition of these infiltrates. This showed that the pre-existent peri-arteriolar B-and T-cell areas were preserved while the red pulp was diffusely infiltrated by Cd3 positive atypical lymphocytes (Figure 2c ). Analysis of proliferation using Ki67 showed that proliferative activity in germinal centers was retained as expected, whereas splenic T-cell lymphomas exhibited a near 100% proliferative index ( Figure   2d ). β-Catenin did not show nuclear labeling in either Apc Min/+ or wild type mice (Figure 2d ). This suggests that the lymphomas developed in an Apc independent manner. This is consistent with the fact that no difference was observed in the severity of lymphoma development between control
and Apc Min/+ mice.
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Azathioprine treatment does not affect adenoma development in Apc Min/+ mice
We next assessed if intestinal adenoma development was affected by the administration of azathioprine. Animals that had received azathioprine (n=6) did not exhibit a significant decrease in polyp numbers compared to Apc Min/+ mice that had received vehicle only (n=6) (48±3.1 vs 59±5.7 adenomas respectively, P = 0.148, Figure 3a) . Furthermore, analysis of adenoma localization and In humans, the major side effects of treatment with azathioprine are gastrointestinal complaints such as nausea and abdominal pain 15 , hepatotoxicity 16 , pancreatitis 17 and bone marrow depression 18 . We observed substantial toxicity in all azathioprine treated mice. Surprisingly, this resulted in significant more morbidity in female mice compared to males. Azathioprine induced toxicity is related to activity of the enzyme thiopurine S-methyltransferase (TPMT) 19, 20 . Thereofore the deficiency of TPMT enzyme activity may cause increased sensitivity to azathioprine induced toxicity 21, 22 . In accordance to this it was recently shown that TPMT enzyme activity was lower in females than compared to males 23 .
Although we did not assess TPMT activity in our experiments, this may explain why female mice were more vulnerable to azathioprine than males.
Thiopurine use is also associated with an increased relative risk but small absolute risk in development of lymphomas [24] [25] [26] . Also in our hands mice display a remarkable susceptibility to develop azathioprineinduced lymphomas. This suggests that the azathioprine may have been over dosed in our experiment or that mice have an increased susceptibility to lymphoma development. Unfortunately we have so far been unable to determine drug levels in mouse blood in our institute. However, since overdosing would more likely result in overestimation of the protective effect of azathioprine, it is unlikely to explain the lack of effect on adenoma development.
The lack of effect of azathioprine on adenoma development in our experiments could be due to The reduced risk of developing colorectal cancer in patients with IBD treated with thiopurines was observed in a retrospective analysis of 2578 patients in which 1% developed advanced neoplasia (high grade dysplasia or colorectal cancer). Whether this association is the result of a better control of inflammation in thiopurine treated patients, a direct effect on inflammation driven carcinogenesis or potential confounding factors will be hard to elucidate. The results from our current study suggest that azathioprine may not prevent Apc dependent sporadic intestinal tumorigenesis.
COMMENTS Background
Treatment with thiopurines is associated with a reduced risk of developing colorectal cancer in patients with inflammatory bowel disease. If thiopurines can also reduce adenoma formation in the absence of inflammation remains thus far unknown.
Research frontiers
The presumed mechanism of action of thiopurines is through selective inhibition of the GTPase RAC1.
It has recently been shown that Rac1 signaling also plays a key role in sporadic intestinal adenoma formation downstream of the mutation in Apc. The Apc gene is frequently mutated in intestinal adenomas and carcinomas and patients with familial adenomatous polyposis (FAP).
Innovations and breakthroughs
The role of azathioprine in inflammation and inflammation associated cancer has been studied extensively. In the current manuscript we report fort the first time that in the absence of inflammation, azathioprine does not reduce adenoma formation in a mouse model of sporadic intestinal tumorigenesis.
Applications
The molecular target of azathioprine, RAC1 has recently been implicated as a critical player during sporadic intestinal tumorigenesis. Given the extensive clinical experience with thiopurines, this may thus be a candidate for chemoprevention of colorectal cancer in patients that have increased risk for developing this disease. Here we tested this hypothesis by treating Apc Min/+ mice with azathioprine and found that azathioprine does not reduce adenoma formation.
Terminology
Rac1 is a member of the Rho family of GTPases and acts as a key-component in diverse signaling pathways and plays a critical role in many cellular processes such as proliferation, apoptosis and migration. Apc Min/+ mice carry a germ line mutation in Apc similar to patients with familial adenomatous polyposis (FAP) and can be used to model FAP specifically or Apc dependent adenoma development more in general.
